热门资讯> 正文

诺华获得英国批准Rhapsido治疗荨麻疹

2026-08-07 01:25

诺华制药(NVS) 0

The UK's Medicines and Healthcare products Regulatory Agency has approved Novartis' (NVS) Rhapsido (remibrutinib) for chronic spontaneous urticaria.
The approval of the BTK inhibitor was based on the results of two trials in patients that failed on an antihistamine. Those on remibrutinib saw greater reductions in itch and hive symptoms compared with placebo.
Rhapsido was approved by the US FDA in 2025.

More on Novartis

Novartis: The Buy Thesis Is Back (Rating Upgrade)
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Novartis gains expanded indication for Pluvicto
Novartis rises as Q2 results beat on both lines

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。